Discover your next big idea at PACK EXPO Las Vegas this September
Experience a breakthrough in packaging & processing and transform your business with solutions from 2,300 suppliers spanning all industries.
REGISTER NOW & SAVE

Sanofi Takes on Rituximab in Asian Biosimilar Market

Sanofi inks deal with Taiwan’s JHL Biotech to create biosimilar that could take over China’s cancer market.

Rituximab / Image: MedPage Today
Rituximab / Image: MedPage Today

A December 6th LabioTech article discussed the partnership formed between French pharmaceutical giant Sanofi and biopharmaceutical manufacturer JHL Biotech. The two companies recently signed a $236M deal for Sanofi to gain exclusive rights to commercialize JHL’s rituximab biosimilar in China. Rituximab is Roche’s top-selling biological and the second top-selling biological overall, bringing in $7.22 billion last year.

Rituximab is a monoclonal antibody that destroys B cells to treat diseases like lymphoma, leukemia, transplant rejection and autoimmune disorders. Novartis’ Sandoz is pulling ahead in the U.S. and Europe markets with its rituximab biosimilar, which is already under review for approval by the FDA and EMA. Amgen and Pfizer both have dogs in the fight with their own rituximab competitors in clinical development.

Break out of the ordinary: see what’s new in packaging & processing!
At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us this September to experience a breakthrough in packaging and processing.
REGISTER NOW AND SAVE
Break out of the ordinary: see what’s new in packaging & processing!
Annual Outlook Report: Sustainability
The road ahead for CPGs in 2025 and beyond—<i>Packaging World</i> editors review key findings from a survey of 88 brand owners, CPG, and FMCG readers.
Download Now
Annual Outlook Report: Sustainability